title: Bioequivalence of two formulations of piroxicam.
abstract: Two separate studies were performed with 12 volunteers in order to demonstrate the bioequivalence of 2 piroxicam (CAS 36322-90-4) tablet and 2 piroxicam suppository formulations after single dose administration. A validated reversed-phase HPLC method with UV-detection is described. Bioequivalence assessment was done by using the posterior probability of a mean ratio between 0.8 and 1.2, and by using the Two One-Sided Tests Procedure (i.e. the 90% confidence interval). The probability approach and the confidence interval approach were compared.
authors.affiliation: Laboratory for Pharmaceutical Chemikstry and Drug analysis, Vrije Universiteit Brussel (Belgium)
authors.forename: Y
authors.initials: Y
authors.lastname: Michotte
authors.forename: H P
authors.initials: HP
authors.lastname: Van Klaveren
authors.forename: M R
authors.initials: MR
authors.lastname: Detaevenier
authors.forename: C F
authors.initials: CF
authors.lastname: Gusdorf
authors.lastname: Vanhaelst
mesh_terms: D000328:Adult; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D008297:Male; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D013488:Suppositories; D013607:Tablets; D013810:Therapeutic Equivalency
chemical_list: D013488:Suppositories; D013607:Tablets; D010894:Piroxicam